相关实验视频

Updated: May 29, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

在患有癌原驱动性非小细胞肺癌的患者中,PD-1阻断加化疗的有效性

Haowei Wang¹, Lei Cheng², Jian Chen³

¹Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, No. 507 Zhengmin Road, Shanghai, 200433, China.

Cancer immunology, immunotherapy : CII

|February 1, 2025

概括

对于具有致癌驱动因素的高级非小细胞肺癌 (NSCLC),PD-1阻断加上化疗与单一治疗相比显著改善了结果. 这种组合疗法显示出卓越的疗效,特别是在KRAS,EGFR和BRAF突变子组中.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
遗传学是一个遗传学.

背景情况:

具有致癌驱动因素的高级非小细胞肺癌 (NSCLC) 对目前的治疗反应有限.
PD-1阻断加上化疗是无驱动器NSCLC的标准,但其在驱动器突变NSCLC的疗效尚不清楚.

研究的目的:

评估PD-1阻断加上化疗在具有瘤驱动因素的晚期NSCLC患者的疗效.
为了比较组合治疗与单一治疗在特定驱动突变子组的结果.

主要方法:

对312名患有瘤致癌驱动因素的NSCLC患者进行了回顾性分析.
治疗组之间的客观应答率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS) 的比较 (PD-1加化疗,PD-1单疗,仅化疗).

主要成果:

与单独治疗相比,PD-1阻塞加上化疗导致ORR显著更高 (51%对18%对25%),PFS中位数更长 (10.0对3.7对5.3个月),和改善的中位数OS (26.0对14.3对16.1个月) 与单独治疗相比 (P < 0.001).
在一线和后一线治疗中观察到卓越的疗效.
患有KRAS,EGFR或BRAF突变的患者在组合治疗中显著改善了PFS和OS.

结论:

对于致癌驱动的先进NSCLC,PD-1阻断加上化疗比单疗更有效.
这种组合疗法是KRAS,EGFR或BRAF突变患者的潜在治疗选择,特别是当有针对性的疗法无法使用时.

关键词:

有效性有效性.非小细胞肺癌的非小细胞肺癌.瘤性驱动因素瘤性驱动因素在PD-1封锁中.

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...